Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Making Strides Against a Rare Disease: Renal Medullary Carcinoma in Focus

June 8th 2017

Renal medullary carcinoma is a rare but devastating tumor type almost exclusively affecting young adults carrying 1 copy of hemoglobin beta (HBB) harboring the A17T mutation (HbS).

Dr. Choueiri on Avelumab Plus Axitinib in mRCC

June 8th 2017

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses phase I results of axitinib (Inlyta) plus avelumab (Bavencio) for the treatment of patients with metastatic renal cell carcinoma (RCC).

A Whirlwind of Changes in Kidney Cancer Brings Optimism

June 7th 2017

The pharmacologic treatment for advanced renal cell carcinoma has evolved considerably since the FDA approved interleukin-2 as the first systemic therapy for the tumor type in 1992. Since then, the FDA has approved more than 20 drugs for RCC in the past 12 years.

Avelumab/Axitinib Combo Shows Promise in Frontline RCC

June 7th 2017

Combining the PD-L1 inhibitor avelumab (Bavencio) with the VEGF inhibitor axitinib (Inlyta) as a frontline regimen induced a response rate of 58.2% in patients with advanced renal cell carcinoma, according to findings from the phase Ib JAVELIN Renal 100 trial presented at the 2017 ASCO Annual Meeting.

Dr. Badani on the Future of Robotic Surgery for Kidney Cancer

June 6th 2017

Ketan K. Badani, MD, professor of Urology at Mount Sinai Hospital, discusses the future of robotic surgery for patients with kidney cancer.

Pembrolizumab/ Epacadostat Combo Active in Urothelial Carcinoma

June 6th 2017

Combining the PD-1 inhibitor pembrolizumab with the IDO1 inhibitor epacadostat led to an overall response rate of 35% in patients with advanced urothelial carcinoma.

Dr. Kaouk on the Results of a Study of Robotic Surgery for RCC

June 6th 2017

Jihad Kaouk, MD, urologist, Cleveland Clinic, discusses the results of a study of robot-assisted partial nephrectomy for selected renal mass using an off-clamp approach compared to an on-clamp approach for patients with renal cell carcinoma (RCC).

Dr. Apolo on Updated JAVELIN Results of Avelumab in Urothelial Carcinoma

June 4th 2017

Andrea B. Apolo, MD, principal investigator and the head of the Bladder Cancer Section in the Genitourinary Malignancies Branch at the National Cancer Institute’s Center for Cancer Research, discusses the updated findings of the phase Ib JAVELIN trial exploring avelumab (Bavencio) for the treatment of patients with metastatic urothelial carcinoma.

Dr. Balar on Mature Clinical Results of KEYNOTE-052 in Urothelial Cancer

June 3rd 2017

Arjun V. Balar, MD, assistant professor of medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the mature clinical trial results and biomarker findings of KEYNOTE-052, first-line pembrolizumab (Keytruda) in patients with cisplatin-ineligible advanced urothelial cancer, during the 2017 ASCO Annual Meeting.

FDA Grants Adjuvant Sunitinib Priority Review in High-Risk RCC

June 1st 2017

The FDA has granted a priority review designation to sunitinib (Sutent) for use as an adjuvant therapy in patients with renal cell carcinoma who have received nephrectomy and are high risk for recurrence.

Ramucirumab Improves PFS in Phase III Urothelial Carcinoma Trial

May 31st 2017

Adding ramucirumab (Cyramza) to docetaxel led to a statistically significant improvement in progression-free survival (PFS) versus docetaxel alone in previously treated patients with locally advanced or unresectable or metastatic urothelial carcinoma.

Dr. Kaouk on a Study of Robotic Surgery in Kidney Cancer

May 26th 2017

Jihad Kaouk, MD, urologist, Cleveland Clinic, discusses how robot-assisted partial nephrectomy for selected renal mass using off-clamp approach offered renal functional advantage over on-clamp approach.

Dr. Daneshmand on Blue Light Cystoscopy for Bladder Cancer

May 26th 2017

Siamak Daneshmand, MD, associate professor of Urology, Director of Clinical Research, Keck School of Medicine of USC, discusses blue light cystoscopy compared with white light cystoscopy for patients with bladder cancer.

Post-TURBT Gemcitabine Reduces Recurrence in Bladder Cancer

May 26th 2017

Edward Messing, MD, discusses how treatment with gemcitabine following transurethral resection of bladder tumors reduced the risk of recurrence by 34% in patients with non-muscle invasive disease.

Dr. Badani on the Benefits of Robotic Surgery for Kidney Cancer

May 25th 2017

Ketan K. Badani, MD, professor of Urology at Mount Sinai Hospital, discusses the benefits of performing a partial robotic nephrectomy for patients with kidney cancer.

Dr. Rosenberg on Non-Metastatic Muscle Invasive Bladder Cancer Guidelines

May 25th 2017

Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the new treatment guidelines for patients with non-metastatic muscle invasive bladder cancer.

ODAC Recommends Approval of Epoetin Alfa Biosimilar

May 25th 2017

The FDA’s Oncologic Drugs Committee voted 14-1 to recommend approving a biologics license application for epoetin hospira (Retacrit), an epoetin alfa (Epogen/Procrit) biosimilar manufactured by Hospira.

Dr. Lallas on Immunotherapy Combinations in Genitourinary Malignancies

May 22nd 2017

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses combinations of immunotherapy for genitourinary malignancies.

Lead Researcher Discusses FDA Approval of Pembrolizumab for Urothelial Carcinoma

May 22nd 2017

Arjun V. Balar, MD, discusses the impact of the approval of pembrolizumab and other immunotherapy agents in urothelial carcinoma, as well as the next steps with these treatments.

Precision Medicine Circa 2017

May 20th 2017

Raoul S. Concepcion, MD, discusses the new era of molecular testing and screening and how it has impacted the field of prostate cancer thus far.